S1 2006 Results
Six-month results accompanied by an...
Six-month results accompanied by an ambitious capital expenditure program.
Philippe Decazes, Chairman of the Executive Board commented: "In an expanding market, these investments will lay the groundwork for continued growth and ongoing improvements in margins. In the years ahead, Sinerem, a highly innovative new product, will fuel expansion, joining our current growth drivers, Xenetix and Dotarem"